Canada faces calls for investigation into death of woman after plasma donation

Grifols did not immediately respond to a request for comment about Lanteigne’s comments. But earlier this week, in response to Globe and Mail reporting about the November inspection report, Grifols said it had submitted detailed action plans to Health Canada for immediate implementation. The company also said it would work closely with the regulator to meet its licence requirements.

Lanteigne said she and others had written to Mark Carney, Canada’s prime minister, to ensure an investigation is reopened into Alabede’s death, and that Grifols’s license is suspended in the interim.

Plasma, the pale yellow liquid part of blood, is used to create medications for a number of conditions, including haemophilia, and to help treat burn victims.

Deaths from plasma donation are exceedingly rare. Only three fatalities have been documented in Canada in the last decade, all of which happened in Manitoba.

The Guardian first reported the extent to which Grifols had failed inspection reports at other sites including “validation, calibration, cleaning, or maintenance of critical equipment [that] were not always sufficient” and records that “were not always accurate, complete, legible, indelible and/or readily retrievable”.

Of the eight documented instances of non-compliance for blood inspections, which date back to 2016, facilities operated by Grifols made up half of all cases.

In the case of the Winnipeg site where Alabede died, inspectors found issues dating back to 2022.

Alabede, who moved to Canada from Nigeria to pursue her goals of becoming a social worker, was remembered by friends as “deeply devoted to her dream and always carried herself with grace, warmth, and sincerity”.

Three months after Alabede’s death, another person died while donating plasma at a different location in Winnipeg.

Health Canada said there were immediate visits to the plasma collection centres after each reported fatality and records indicated standard operating procedures were being followed.

But in a chain of internal emails among health officials from February, seen by the Guardian, Health Canada’s director general of compliance enforcement expresses concern after the second death at a plasma donation site.

Grifols said in a statement at the time that it had “no reason to believe that there is a correlation between the donors’ passing and plasma donation”.

In its March medical summary, Health Canada said there was “no linkage” between plasma donation and Abede’s death.

But Lanteigne said there were “profound” discrepancies between the medical examiner’s report and the report that Health Canada has distributed to legislators, including dramatically different volumes of plasma collected.

The Guardian was provided a copy of the autopsy, with a representative of the family’s permission, to confirm the discrepancies.

Questions over the structure of how Canadians give blood and plasma are set against the backdrop of a national scandal in which thousands of Canadians were infected with HIV/Aids and hepatitis C through contaminated blood products in the 1980s and early 90s.

Lanteigne said she was disheartened that no officials ever reached out to the family.

“Nobody has helped this family to find answers as to what happened to [their] daughter,” said Lanteigne “Rodiyat donated that day to save the life of another person. She did not go to Grifols to die.”